Vincent Sarrazy1, Anne Koehler1, Melissa L Chow1, Elena Zimina1, Chen X Li1, Hideyuki Kato2, Christopher A Caldarone2, Boris Hinz3. 1. Laboratory of Tissue Repair and Regeneration, Matrix Dynamics Group, Faculty of Dentistry, University of Toronto, 150 College Street, Toronto, ON, Canada M5S 3E2. 2. Division of Cardiac Surgery, University of Toronto, Toronto, ON, Canada Department of Surgery, Hospital for Sick Children, Labatt Family Heart Center, University of Toronto, Toronto, ON, Canada. 3. Laboratory of Tissue Repair and Regeneration, Matrix Dynamics Group, Faculty of Dentistry, University of Toronto, 150 College Street, Toronto, ON, Canada M5S 3E2 boris.hinz@utoronto.ca.
Abstract
AIMS: Pathological tissue remodelling by myofibroblast contraction is a hallmark of cardiac fibrosis. Myofibroblasts differentiate from cardiac fibroblasts under the action of transforming growth factor-β1 (TGF-β1), which is secreted into the extracellular matrix as a large latent complex. Integrin-mediated traction forces activate TGF-β1 by inducing a conformational change in the latent complex. The mesenchymal integrins αvβ5 and αvβ3 are expressed in the heart, but their role in the activation of TGF-β1 remains elusive. Here, we test whether targeting αvβ5 and αvβ3 integrins reduces latent TGF-β1 activation by cardiac fibroblasts with the goal to prevent the formation of α-smooth muscle actin (α-SMA)-expressing cardiac myofibroblasts and their contribution to fibrosis. METHODS AND RESULTS: Using a porcine model of induced right ventricular fibrosis and pro-fibrotic culture conditions, we show that integrins αvβ5 and αvβ3 are up-regulated in myofibroblast-enriched fibrotic lesions and differentiated cultured human cardiac myofibroblasts. Both integrins autonomously contribute to latent TGF-β1 activation and myofibroblast differentiation, as demonstrated by function-blocking peptides and antibodies. Acute blocking of both integrins leads to significantly reduced TGF-β1 activation by cardiac fibroblast contraction and loss of α-SMA expression, which is restored by adding active TGF-β1. Manipulating integrin protein levels in overexpression and shRNA experiments reveals that both integrins can compensate for each other with respect to TGF-β1 activation and induction of α-SMA expression. CONCLUSIONS: Integrins αvβ5 and αvβ3 both control myofibroblast differentiation by activating latent TGF-β1. Pharmacological targeting of mesenchymal integrins is a possible strategy to selectively block TGF-β1 activation by cardiac myofibroblasts and progression of fibrosis in the heart. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Pathological tissue remodelling by myofibroblast contraction is a hallmark of cardiac fibrosis. Myofibroblasts differentiate from cardiac fibroblasts under the action of transforming growth factor-β1 (TGF-β1), which is secreted into the extracellular matrix as a large latent complex. Integrin-mediated traction forces activate TGF-β1 by inducing a conformational change in the latent complex. The mesenchymal integrins αvβ5 and αvβ3 are expressed in the heart, but their role in the activation of TGF-β1 remains elusive. Here, we test whether targeting αvβ5 and αvβ3 integrins reduces latent TGF-β1 activation by cardiac fibroblasts with the goal to prevent the formation of α-smooth muscle actin (α-SMA)-expressing cardiac myofibroblasts and their contribution to fibrosis. METHODS AND RESULTS: Using a porcine model of induced right ventricular fibrosis and pro-fibrotic culture conditions, we show that integrins αvβ5 and αvβ3 are up-regulated in myofibroblast-enriched fibrotic lesions and differentiated cultured human cardiac myofibroblasts. Both integrins autonomously contribute to latent TGF-β1 activation and myofibroblast differentiation, as demonstrated by function-blocking peptides and antibodies. Acute blocking of both integrins leads to significantly reduced TGF-β1 activation by cardiac fibroblast contraction and loss of α-SMA expression, which is restored by adding active TGF-β1. Manipulating integrin protein levels in overexpression and shRNA experiments reveals that both integrins can compensate for each other with respect to TGF-β1 activation and induction of α-SMA expression. CONCLUSIONS: Integrins αvβ5 and αvβ3 both control myofibroblast differentiation by activating latent TGF-β1. Pharmacological targeting of mesenchymal integrins is a possible strategy to selectively block TGF-β1 activation by cardiac myofibroblasts and progression of fibrosis in the heart. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Kyungmin Hahm; Matvey E Lukashev; Yi Luo; William J Yang; Brian M Dolinski; Paul H Weinreb; Kenneth J Simon; Li Chun Wang; Diane R Leone; Roy R Lobb; Donald J McCrann; Normand E Allaire; Gerald S Horan; Agnes Fogo; Raghu Kalluri; Charles F Shield; Dean Sheppard; Humphrey A Gardner; Shelia M Violette Journal: Am J Pathol Date: 2007-01 Impact factor: 4.307
Authors: R Gisli Jenkins; Xiao Su; George Su; Christopher J Scotton; Eric Camerer; Geoffrey J Laurent; George E Davis; Rachel C Chambers; Michael A Matthay; Dean Sheppard Journal: J Clin Invest Date: 2006-05-18 Impact factor: 14.808
Authors: Bruce Wang; Brian M Dolinski; Noriko Kikuchi; Diane R Leone; Marion G Peters; Paul H Weinreb; Shelia M Violette; D Montgomery Bissell Journal: Hepatology Date: 2007-11 Impact factor: 17.425
Authors: Gerald S Horan; Susan Wood; Victor Ona; Dan Jun Li; Matvey E Lukashev; Paul H Weinreb; Kenneth J Simon; Kyungmin Hahm; Normand E Allaire; Nicola J Rinaldi; Jaya Goyal; Carol A Feghali-Bostwick; Eric L Matteson; Carl O'Hara; Robert Lafyatis; Gerald S Davis; Xiaozhu Huang; Dean Sheppard; Shelia M Violette Journal: Am J Respir Crit Care Med Date: 2007-10-04 Impact factor: 21.405
Authors: Amy McCurley; Stella Alimperti; Silvia B Campos-Bilderback; Ruben M Sandoval; Jenna E Calvino; Taylor L Reynolds; Catherine Quigley; Joshua W Mugford; William J Polacheck; Ivan G Gomez; Jennifer Dovey; Graham Marsh; Angela Huang; Fang Qian; Paul H Weinreb; Brian M Dolinski; Shaun Moore; Jeremy S Duffield; Christopher S Chen; Bruce A Molitoris; Shelia M Violette; Michael A Crackower Journal: J Am Soc Nephrol Date: 2017-01-06 Impact factor: 10.121
Authors: Chen Xi Li; Nilesh P Talele; Stellar Boo; Anne Koehler; Ericka Knee-Walden; Jenna L Balestrini; Pam Speight; Andras Kapus; Boris Hinz Journal: Nat Mater Date: 2016-10-31 Impact factor: 43.841
Authors: Joshua G Travers; Fadia A Kamal; Jeffrey Robbins; Katherine E Yutzey; Burns C Blaxall Journal: Circ Res Date: 2016-03-18 Impact factor: 17.367